Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden. US Non-Farm Payrolls predicted to show moderate employment growth in JanuaryJanuary’s US Non-Farm Payrolls are forecast to show a 169K job increase, with unemployment steady at 4.1%. Wage growth may ease, influencing Fed policy and market expectations.
21 hours ago
The year in review – a relentlessly dynamic 20242024 brought a gold boom, a dovish turn for central banks, endless macroeconomic upheaval, and so much more.
13:37, 3 February 2025
Market Analysis: Europe feels the pinch of Trump’s tariffs and higher CPIEuropean stocks face downside pressure as Trump’s tariff threats weigh on investor sentiment.
11:56, 3 February 2025
Risk-off prevails as Trump-tariffs raise risks to global growthGlobal markets turn risk-off as Trump imposes new tariffs on Mexico, Canada, and China.
09:49, 3 February 2025